Literature DB >> 7515549

Integrin expression in middle ear cholesteatoma.

S Dallari1, A Cavani, G Bergamini, G Girolomoni.   

Abstract

Cholesteatoma is lined by a squamous keratinizing epithelium exhibiting most of the features of normal epidermis. In this study, we investigated by immunohistochemistry the expression of integrin adhesion molecules in primary acquired and recurrent cholesteatomas, and compared it with common epidermal cysts and normal human skin. The results showed that cholesteatoma epithelium exhibited a markedly augmented expression of alpha v integrin subunit and a corresponding increased deposition of vitronectin (alpha v ligand) in the surrounding stroma as compared to epidermal cyst and normal human skin. In contrast, the expression pattern of alpha 2 beta 1, alpha 3 beta 1, and alpha 6 beta 4 integrins as well as the distribution of laminin, collagen IV and fibronectin were similar in cholesteatomas, epidermal cysts and normal human skin. Similar staining pattern was observed in primary acquired and recurrent cholesteatoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515549     DOI: 10.3109/00016489409126040

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  3 in total

Review 1.  Etiopathogenesis of cholesteatoma.

Authors:  Ewa Olszewska; Mathias Wagner; Manuel Bernal-Sprekelsen; Jörg Ebmeyer; Stefan Dazert; Henning Hildmann; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-27       Impact factor: 2.503

2.  Comparative analysis of the epithelium stroma interaction of acquired middle ear cholesteatoma in children and adults.

Authors:  Hans-J Welkoborsky; Roland S Jacob; Mike L Hinni
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-06-01       Impact factor: 2.503

3.  Large-scale proteomics differentiates cholesteatoma from surrounding tissues and identifies novel proteins related to the pathogenesis.

Authors:  Anders Britze; Rune Isak Dupont Birkler; Niels Gregersen; Therese Ovesen; Johan Palmfeldt
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.